ArticleExperimental hematology & oncology2025

Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma.

Wenming Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.